Free Trial
NYSE:BHC

Bausch Health Cos Q3 2025 Earnings Report

Bausch Health Cos logo
$6.68 +0.14 (+2.06%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$6.68 0.00 (0.00%)
As of 10/3/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch Health Cos EPS Results

Actual EPS
N/A
Consensus EPS
$1.12
Beat/Miss
N/A
One Year Ago EPS
N/A

Bausch Health Cos Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.61 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bausch Health Cos Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Wednesday, October 29, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

Bausch Health Cos Earnings Headlines

URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
See More Bausch Health Cos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bausch Health Cos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bausch Health Cos and other key companies, straight to your email.

About Bausch Health Cos

Bausch Health Cos (NYSE:BHC) Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices. Bausch + Lomb is also active in aesthetics with products used in ophthalmic surgery and ocular cosmetics. In its Diversified Brands segment, the company delivers a portfolio of dermatology treatments for both prescription and consumer use, gastrointestinal therapies for irritable bowel syndrome and ulcerative colitis, as well as neurology products targeting migraine prevention and treatment.

Tracing its roots back to a Canadian pharmaceutical firm founded in 1959, the company underwent significant expansion after acquiring Bausch + Lomb in 2013 under the Valeant name. In May 2018, the enterprise rebranded as Bausch Health Companies Inc to reflect a renewed focus on core pharmaceutical and eye health operations. Today, it maintains manufacturing sites and research facilities across North America, Europe, Latin America and Asia-Pacific, serving patients and healthcare professionals in more than 100 countries.

Under the leadership of President and Chief Executive Officer Joseph C. Cacciatore, Bausch Health has pursued portfolio optimization, debt reduction and a disciplined approach to research and development. The company continues to invest in its pipeline of specialty medicines and eye health solutions, while seeking to enhance access to care through strategic partnerships and targeted licensing agreements around the world.

View Bausch Health Cos Profile

More Earnings Resources from MarketBeat